Predictive animal models of mania: Hits, misses and future directions

British Journal of Pharmacology

Volumn 164, Issue 4, 2011, Pages 1263-1284

  Young, Jared W ^a   Henry, Brook L ^a   Geyer, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

activity; animal models; cognition; environmental; false positives; genetic; mania; mice; pharmacological; rats

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CARNOSINE; CHLORPROMAZINE; GABAPENTIN; GALANTAMINE; GLYCOGEN SYNTHASE KINASE 3; HALOPERIDOL; INOSITOL PHOSPHATE; INSULIN; LAMOTRIGINE; LITHIUM CARBONATE; MEMANTINE; METHYLENE BLUE; OLANZAPINE; OXCARBAZEPINE; PLACEBO; PRAMIPEXOLE; PROTEIN KINASE C; QUETIAPINE; RISPERIDONE; TAMOXIFEN; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; WITHANIA SOMNIFERA EXTRACT; ZIPRASIDONE;

ANIMAL BEHAVIOR; BEACH RAFAELSON MANIA SCALE; BIPOLAR MANIA; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE DEFECT; COMPETITIVE BEHAVIOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE MODEL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; FALSE POSITIVE RESULT; FOOD INTAKE; FOOTSHOCK; GENETIC ANALYSIS; GENETIC MANIPULATION; HABITUATION; HUMAN; HYPERACTIVITY; HYPERSEXUALITY; INPATIENT MULTIDIMENSIONAL PSYCHIATRIC SCALE; IRRITABILITY; LOCOMOTION; MANIA; MENTAL DISEASE; MOOD DISORDER; MULTICENTER STUDY (TOPIC); NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; PHARMACOGENETICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHEDULE FOR AFFECTIVE DISORDERS AND SCHIZOPHRENIA; SLEEP; SLEEP DEPRIVATION; SPECIES DIFFERENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; MALE; MICE; MODELS, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RATS; REPRODUCIBILITY OF RESULTS;

EID: 80052293065     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01318.x     Document Type: Review

References (232)

1. Amsterdam, JD, Newberg, AB, (2007). A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controls. Neuropsychobiology 55: 167-170. (Pubitemid 47525236)
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
3. APA (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159: 1-50.
4. Arban, R, Maraia, G, Brackenborough, K, Winyard, L, Wilson, A, Gerrard, P, et al,. (2005). Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav Brain Res 158: 123-132. (Pubitemid 40174717)
5. Agarwal V, Tripathi A, (2009). Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry 51: 137-138.
6. Arora M, Daughton J, (2007). Mania in the medically ill. Curr Psychiatry Rep 9: 232-235. (Pubitemid 46895101)
7. Atack J, (2000). Lithium, phosphatidylinositol signaling and bipolar disorder. In:, Manji HK, Bowden CL, Belmaker RH, (eds). Bipolar Medications: Mechanisms of Action. American Psychiatric Press: Washington DC, pp. 1-30.
8. Baastrup PC, Schou M, (1967). Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16: 162-172.
9. Bauer MS, Crits-Christoph P, Ball WA, Dewees E, McAllister T, Alahi P, et al,. (1991). Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania. Arch Gen Psychiatry 48: 807-812.
10. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, et al,. (1999). Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 60: 9-21. (Pubitemid 29069880)
11. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK, (2000). A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 57: 95-97. (Pubitemid 30035669)
12. Benedetti F, Fresi F, Maccioni P, Smeraldi E, (2008). Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res 187: 221-227.
13. Berggren U, Tallstedt L, Ahlenius S, Engel J, (1978). The effect of lithium on amphetamine-induced locomotor stimulation. Psychopharmacology (Berl) 59: 41-45. (Pubitemid 9013403)
14. Berrios GE, (1988). Depressive and manic states during the nineteenth century. In:, Georgotas A, Cancro R, (eds). Depression and Mania. Elsevier: New York, pp. 13-25.
15. Bora E, Yucel M, Pantelis C, (2009). Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 113: 1-20.
16. Borkowska A, Rybakowski JK, (2001). Neuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar. Bipolar Disord 3: 88-94. (Pubitemid 32492596)
17. Bourin M, Lambert O, Guitton B, (2005). Treatment of acute mania-from clinical trials to recommendations for clinical practice. Hum Psychopharmacol 20: 15-26. (Pubitemid 40227641)
18. Bowden CL, (2002). Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 3: 1513-1519. (Pubitemid 35174883)
19. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al,. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271: 918-924. (Pubitemid 24083217)
20. Bowden CL, Mitchell P, Suppes T, (1999). Lamotrigine in the treatment of bipolar depression. Eur Neuropsychopharmacol 9 (Suppl. 4): S113-S117. (Pubitemid 29397411)
21. Bowden C, Singh V, (2006). Valproate: clinical pharmacological profile. In:, Akiskal H, Tohen M, (eds). Bipolar Psychopharmacology. John Wiley & Sons: Chichester, pp. 27-42.
22. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L, (1978). Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15: 339-343. (Pubitemid 9016401)
23. Braff DL, Geyer MA, Swerdlow NR, (2001). Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258. (Pubitemid 32705488)
24. Brain PF, Al-Maliki S, (1979). Effects of lithium chloride injections on rank-related fighting, maternal aggression and locust-killing responses in naive and experienced 'TO' strain mice. Pharmacol Biochem Behav 10: 663-669. (Pubitemid 9215081)
25. Brambilla P, Soares J, (2005). The use of anticonvulsants in treatment of bipolar disorder. In:, Kasper S, Hirschdelf RM, (eds). Handbook of Bipolar Disorder. Taylor & Francis: Boca Raton, pp. 285-314.
26. Brody SA, Geyer MA, Large CH, (2003). Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169: 240-246. (Pubitemid 37255516)
27. Bunney WE, Jr, Goodwin FK, Davis JM, Fawcett JA, (1968). A behavioral-biochemical study of lithium treatment. Am J Psychiatry 125: 499-512.
28. Burdick KE, Braga RJ, Goldberg JF, Malhotra AK, (2007). Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs 21: 971-981. (Pubitemid 350136781)
29. Cade JF, (1949). Lithium salts in the treatment of psychotic excitement. Med J Aust 2: 349-352.
30. Cade J, (1978). Lithium-past,present and future. In:, Johnson FN, Johnson s, (eds). Lithium in Medical Practice. MTP Press: Lancaster, pp. 1-16.
31. Cagniard B, Balsam PD, Brunner D, Zhuang X, (2006). Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31: 1362-1370.
32. Camarasa J, Rodrigo T, Pubill D, Escubedo E, (2010). Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res 62: 450-456.
33. Cappeliez P, Moore E, (1990). Effects of lithium on an amphetamine animal model of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 14: 347-358. (Pubitemid 20191899)
34. Cassidy F, Forest K, Murry E, Carroll BJ, (1998a). A factor analysis of the signs and symptoms of mania. Arch Gen Psychiatry 55: 27-32. (Pubitemid 28069036)
35. Cassidy F, Murry E, Forest K, Carroll BJ, (1998b). Signs and symptoms of mania in pure and mixed episodes. J Affect Disord 50: 187-201. (Pubitemid 28551788)
36. Chipana C, Camarasa J, Pubill D, Escubedo E, (2008a). Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 29: 179-183.
37. Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E, (2008b). Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 54: 1254-1263.
38. Chiu CT, Chuang DM, (2010). Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128: 281-304.
39. Cilia J, Gartlon JE, Shilliam C, Dawson LA, Moore SH, Jones DN, (2010). Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J Psychopharmacol 24: 407-419.
40. Cookson J, (2006). Haloperidol and risperidone in mania. In:, Akiskal H, Tohen M, (eds). Bipolar Psychopharmacotherapy. John Wiley & Sons: Chichester, pp. 105-123.
41. Correll CU, Sheridan EM, DelBello MP, (2010). Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12: 116-141.
42. Costall B, Domeney AM, Kelly ME, Naylor RJ, Tomkins DM, (1990). Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 35: 607-615. (Pubitemid 20115748)
43. Cruceanu C, Alda M, Rouleau G, Turecki G, (2006). Response to treatment in bipolar disorder. Curr Opin Psychiatry 24: 24-28.
44. Davies JA, Jackson B, Redfern PH, (1974). The effect of amantadine, L-dopa, (plus)-amphetamine and apomorphine on the acquisition of the conditioned avoidance response. Neuropharmacology 13: 199-204.
45. Decker S, Grider G, Cobb M, Li XP, Huff MO, El-Mallakh RS, et al,. (2000). Open field is more sensitive than automated activity monitor in documenting ouabain-induced hyperlocomotion in the development of an animal model for bipolar illness. Prog Neuropsychopharmacol Biol Psychiatry 24: 455-462. (Pubitemid 30261828)
46. Dencker D, Husum H, (2010). Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res 207: 78-83.
47. Dencker D, Dias R, Pedersen ML, Husum H, (2008). Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav 12: 49-53. (Pubitemid 350246381)
48. Depue RA, Krauss SP, Spoont MR, (1987). A two-dimensional model of seasonal affective bipolar disorder. In:, Magnusson D, Ohman A, (eds). Psychopathology: An Interactionist Perspective. Academic Press: New York, pp. 95-123.
49. DiazGranados N, Zarate CA, Jr, (2008). A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep 10: 510-519.
50. Doyle AE, Wilens TE, Kwon A, Seidman LJ, Faraone SV, Fried R, et al,. (2005). Neuropsychological functioning in youth with bipolar disorder. Biol Psychiatry 58: 540-548. (Pubitemid 41457299)
51. Eagle DM, Baunez C, (2010). Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition. Neurosci Biobehav Rev 34: 50-72.
52. Ehlers CL, Frank E, Kupfer DJ, (1988). Social zeitgebers and biological rhythms. A unified approach to understanding the etiology of depression. Arch Gen Psychiatry 45: 948-952.
53. Eichelman B, Thoa NB, Perez-Cruet J, (1973). Alkali metal cations: effects on aggression and adrenal enzymes. Pharmacol Biochem Behav 1: 121-123.
54. Einat H, (2006). Modelling facets of mania-new directions related to the notion of endophenotypes. J Psychopharmacol 20: 714-722. (Pubitemid 44315872)
55. Einat H, (2007a). Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci Biobehav Rev 31: 850-857. (Pubitemid 47285345)
56. Einat H, (2007b). Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav Genet 37: 244-255. (Pubitemid 46144059)
57. Ellenbroek BA, (1993). Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57: 1-78. (Pubitemid 23130739)
58. el-Mallakh RS, Harrison LT, Li R, Changaris DG, Levy RS, (1995). An animal model for mania: preliminary results. Prog Neuropsychopharmacol Biol Psychiatry 19: 955-962.
59. El-Mallakh RS, Decker S, Morris M, Li XP, Huff MO, El-Masri MA, et al,. (2006). Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 30: 1261-1264. (Pubitemid 44216066)
60. Feifel D, Melendez G, Shilling PD, (2004). Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology 29: 731-738. (Pubitemid 38402480)
61. Feifel D, Melendez G, Priebe K, Shilling PD, (2007). The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res 181: 278-286. (Pubitemid 46898666)
62. Fessler RG, Sturgeon RD, London SF, Meltzer HY, (1982). Effects of lithium on behaviour induced by phencyclidine and amphetamine in rats. Psychopharmacology (Berl) 78: 373-376. (Pubitemid 13218578)
63. Fisher G, Pelonero AL, Ferguson C, (1991). Mania precipitated by prednisone and bromocriptine. Gen Hosp Psychiatry 13: 345-346.
64. Flaisher-Grinberg S, Overgaard S, Einat H, (2009). Attenuation of high sweet solution preference by mood stabilizers: a possible mouse model for the increased reward-seeking domain of mania. J Neurosci Methods 177: 44-50.
65. Fleck DE, Shear PK, Zimmerman ME, Getz GE, Corey KB, Jak A, et al,. (2003). Verbal memory in mania: effects of clinical state and task requirements. Bipolar Disord 5: 375-380. (Pubitemid 37361354)
66. Flood DG, Choinski M, Marino MJ, Gasior M, (2009). Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice. Psychopharmacology (Berl) 205: 369-377.
67. Fountoulakis KN, Vieta E, (2008). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 11: 999-1029.
68. Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, et al,. (2005). Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 62: 996-1004. (Pubitemid 41248379)
69. Fratta W, Collu M, Martellotta MC, Pichiri M, Muntoni F, Gessa GL, (1987). Stress-induced insomnia: opioid-dopamine interactions. Eur J Pharmacol 142: 437-440. (Pubitemid 18063964)
70. Frau R, Orru M, Fa M, Casti A, Manunta M, Fais N, et al,. (2007). Effects of topiramate on the prepulse inhibition of the acoustic startle in rats. Neuropsychopharmacology 32: 320-331. (Pubitemid 46106939)
71. Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, et al,. (2006). Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31: 326-332. (Pubitemid 44497429)
72. Fullerton CA, Busch AB, Frank RG, (2010). The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care 48: 372-379.
73. Gardner R, Jr, (1982). Mechanisms in manic-depressive disorder: an evolutionary model. Arch Gen Psychiatry 39: 1436-1441. (Pubitemid 13240546)
74. Gessa GL, Pani L, Fadda P, Fratta W, (1995). Sleep deprivation in the rat: an animal model of mania. Eur Neuropsychopharmacol 5 (Suppl.): 89-93. (Pubitemid 26017265)
75. Geyer MA, (2006a). Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci 8: 9-16.
76. Geyer MA, (2006b). The family of sensorimotor gating disorders: comorbitities or diagnostic overlaps. Neurotox Res 10: 211-220.
77. Geyer MA, (2008). Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 14: 71-78.
78. Geyer MA, Ellenbroek B, (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27: 1071-1079. (Pubitemid 37464953)
79. Geyer MA, Moghaddam B, (2002). Animal models relevant to schizophrenia disorders. In:, Davis KL, Charney DS, Coyle JT, Nemeroff C, (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams and Wilkins: Philadelphia, pp. 689-701.
80. Geyer MA, Russo PV, Masten VL, (1986). Multivariate assessment of locomotor behavior: pharmacological and behavioral analyses. Pharmacol Biochem Behav 25: 277-288. (Pubitemid 16040937)
81. Ghaemi SN, Wingo AP, Filkowski MA, Baldessarini RJ, (2008). Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand 118: 347-356.
82. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG, (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612. (Pubitemid 26052818)
83. Goldberg JF, Burdick KE, (2001). Cognitive side effects of anticonvulsants. J Clin Psychiatry 62 (Suppl. 14): 27-33. (Pubitemid 32591415)
84. Goldberg JF, Burdick KE, (2002). Levetiracetam for acute mania. Am J Psychiatry 159: 148.
85. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM, (2003). Lamotrigine: a review of its use in bipolar disorder. Drugs 63: 2029-2050. (Pubitemid 37229087)
86. Goodwin FK, Jamison KR, (2007). Manic-Depressive Illness, 2nd edn. Oxford University Press: New York.
87. Goodwin FK, Murphy DL, Bunney WE, Jr, (1969). Lithium-carbonate treatment in depression and mania. A longitudinal double-blind study. Arch Gen Psychiatry 21: 486-496.
88. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E, (2008). Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 18: 787-793.
89. Gould TD, Einat H, (2007). Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 31: 825-831. (Pubitemid 47285353)
90. Gould TJ, Keith RA, Bhat RV, (2001). Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 118: 95-105. (Pubitemid 32037118)
91. Grandjean EM, Aubry JM, (2009). Lithium: updated human knowledge using an evidence-based approach: part I: clinical efficacy in bipolar disorder. CNS Drugs 23: 225-240.
92. Green MF, (2006a). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67 (Suppl. 9): 3-8. discussion 36-42. (Pubitemid 44369648)
93. Green MF, (2006b). Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 67: e12.
94. Greenwood TA, Alexander M, Keck PE, McElroy S, Sadovnick AD, Remick RA, et al,. (2001). Evidence for linkage disequilibrium between the dopamine transporter and bipolar disorder. Am J Med Genet 105: 145-151. (Pubitemid 32290577)
95. Greenwood TA, Schork NJ, Eskin E, Kelsoe JR, (2006). Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11: 125-133, 115. (Pubitemid 43164613)
96. Grunze H, Langosch J, Born C, Schaub G, Walden J, (2003). Levetiracetam in the treatment of acute mania: an open add-on study with an on-off-on design. J Clin Psychiatry 64: 781-784. (Pubitemid 36897214)
97. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al,. (2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 10: 85-116.
98. Gualtieri CT, Johnson LG, (2006). Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. MedGenMed 8: 46.
99. Harrison-Read PE, (2009). Models of mania and antimanic drug actions: progressing the endophenotype approach. J Psychopharmacol 23: 334-337.
100. Hartigan GP, (1963). The use of lithium salts in affective disorders. Br J Psychiatry 109: 810-814.
101. Hasler G, Drevets WC, Gould TD, Gottesman II, Manji HK, (2006). Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 60: 93-105. (Pubitemid 44026591)
102. Henry BL, Minassian A, Young JW, Paulus MP, Geyer MA, Perry W, (2010). Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev 34: 1296-1306.
103. Hicks RA, Moore JD, Hayes C, Phillips N, Hawkins J, (1979). REM sleep deprivation increases aggressiveness in male rats. Physiol Behav 22: 1097-1100. (Pubitemid 10226605)
104. Hirschfeld RM, Kasper S, (2004). A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 7: 507-522. (Pubitemid 39648082)
105. Horschitz S, Hummerich R, Lau T, Rietschel M, Schloss P, (2005). A dopamine transporter mutation associated with bipolar affective disorder causes inhibition of transporter cell surface expression. Mol Psychiatry 10: 1104-1109. (Pubitemid 43251100)
106. Hummel B, Walden J, Stampfer R, Dittmann S, Amann B, Sterr A, Schaefer M, Frye MA, Grunze H, (2002). Acute antimanic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design. Bipolar Disord 4: 412-417. (Pubitemid 36041472)
107. Iosifescu DV, Moore CM, Deckersbach T, Tilley CA, Ostacher MJ, Sachs GS, et al,. (2009). Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci Ther 15: 309-319.
108. Jackson S, (1986). Melancholia and Depression: From Hippocratic Times to Modern Times. Yale University Press: New Haven, CT.
109. Jochum T, Bar KJ, Sauer H, (2002). Topiramate induced manic episode. J Neurol Neurosurg Psychiatry 73: 208-209.
110. Johnson G, Gershon S, Hekimian LJ, (1968). Controlled evaluation of lithium and chlorpromazine in the treatment of manic states: an interim report. Compr Psychiatry 9: 563-573.
111. Johnson G, Gershon S, Burdock EI, Floyd A, Hekimian L, (1971). Comparative effects of lithium and chlorpromazine in the treatment of acute manic states. Br J Psychiatry 119: 267-276.
112. Kato T, Kubota M, Kasahara T, (2007). Animal models of bipolar disorder. Neurosci Biobehav Rev 31: 832-842. (Pubitemid 47285348)
113. Keck PE, Jr, McElroy SL, (2006). A comparison of the 'Second Generation Antipsychotics' in the treatment for bipolar disorder: focus on Clozapine, Quetiapine, Ziprasidone, and Aripiprazole. In:, Akiskal H, Tohen M, (eds). Bipolar Psychopharmacotherapy. John Wiley & Sons: Chichester, pp. 125-134.
114. Keck PE Jr, Mendlwicz J, Calabrese JR, Fawcett J, Suppes T, Vestergaard PA, et al,. (2000). A review of randomized, controlled clinical trials in acute mania. J Affect Disord 59 (Suppl. 1): S31-S37. (Pubitemid 32162873)
115. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G, (2003). A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160: 1651-1684.
116. Keck PE Jr, Hsu HA, Papadakis K, Russo J, Jr, (2009a). Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 32: 199-204.
117. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, et al,. (2009b). Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 112: 36-49.
118. Kelly MP, Logue SF, Dwyer JM, Beyer CE, Majchrowski H, Cai Z, et al,. (2009). The supra-additive hyperactivity caused by an amphetamine- chlordiazepoxide mixture exhibits an inverted-U dose-response: negative implications for the use of a model in screening for mood stabilizers. Pharmacol Biochem Behav 92: 649-654.
119. Kelsoe JR, Sadovnick AD, Kristbjarnarson H, Bergesch P, Mroczkowski-Parker Z, Drennan M, et al,. (1996). Possible locus for bipolar disorder near the dopamine transporter on chromosome 5. Am J Med Genet 67: 533-540.
120. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M, (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 187: 229-234. (Pubitemid 41306103)
121. Kim SH, Yu HS, Park HG, Jeon WJ, Song JY, Kang UG, et al,. (2008). Dose-dependent effect of intracerebroventricular injection of ouabain on the phosphorylation of the MEK1/2-ERK1/2-p90RSK pathway in the rat brain related to locomotor activity. Prog Neuropsychopharmacol Biol Psychiatry 32: 1637-1642.
122. Koszewska I, Rybakowski JK, (2009). Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 59: 12-16.
123. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G, (2010). Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 12: 348-349.
124. Kozikowski AP, Gaisina IN, Yuan H, Petukhov PA, Blond SY, Fedolak A, et al,. (2007). Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders. J Am Chem Soc 129: 8328-8332. (Pubitemid 47035143)
125. Kraepelin E, (1899). Psychiatrie. Ein Lehrbuch Für Studirende Und Aerzte. Sechste, Vollständig Umgearbeitete Auflage, 2 Vols. Leipzig: Barth.
126. Kruger S, Sarkar R, Pietsch R, Hasenclever D, Braunig P, (2008). Levetiracetam as monotherapy or add-on to valproate in the treatment of acute mania-a randomized open-label study. Psychopharmacology (Berl) 198: 297-299.
127. Kulkarni J, Garland KA, Scaffidi A, Headey B, Anderson R, de Castella A, et al,. (2006). A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 31: 543-547. (Pubitemid 43375956)
128. Kushner SF, Khan A, Lane R, Olson WH, (2006). Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 8: 15-27. (Pubitemid 43356017)
129. Lambert PA, Carraz G, Borselli S, Carbel S, (1966). [Neuropsychotropic action of a new anti-epileptic agent: depamide]. Ann Med Psychol (Paris) 124: 707-710.
130. Lamberty Y, Margineanu DG, Klitgaard H, (2001). Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav 2: 454-459. (Pubitemid 33585802)
131. Lattimore R, (1961). The Iliad of Homer (Transl.). University of Chicago Press: Chicago.
132. Legrand R, Fielder R, (1973). Role of dominance-submission relationships in shock-induced fighting of mice. J Comp Physiol Psychol 82: 501-506.
133. Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J, et al,. (2008). Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 147B: 134-166. (Pubitemid 351355275)
134. Leonhard K, (1957). Aufteiling Der Endogenen Psychosen Und Ihre Differenzierte Aetiologie. Akademie-Verlag: Berlin.
135. Li R, el-Mallakh RS, Harrison L, Changaris DG, Levy RS, (1997). Lithium prevents ouabain-induced behavioral changes. Toward an animal model for manic depression. Mol Chem Neuropathol 31: 65-72. (Pubitemid 27328637)
136. Liddell HG, Scott R, (1940). A Greek-English Lexicon. Clarendon Press: Oxford.
137. Luneberg H, (1897). Hippocrates. Sämtliche werke: München.
138. Madden GJ, Ewan EE, Lagorio CH, (2007). Toward an animal model of gambling: delay discounting and the allure of unpredictable outcomes. J Gambl Stud 23: 63-83.
139. Maggs R, (1963). Treatment of manic illness with lithium carbonate. Br J Psychiatry 109: 56-65.
140. Malatynska E, Knapp RJ, (2005). Dominant-submissive behavior as models of mania and depression. Neurosci Biobehav Rev 29: 715-737. (Pubitemid 40755462)
141. Malatynska E, Pinhasov A, Crooke JJ, Smith-Swintosky VL, Brenneman DE, (2007). Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. J Neurosci Methods 165: 175-182. (Pubitemid 47225123)
142. Malkesman O, Austin DR, Chen G, Manji HK, (2009). Reverse translational strategies for developing animal models of bipolar disorder. Dis Model Mech 2: 238-245.
143. Malkoff-Schwartz S, Frank E, Anderson BP, Hlastala SA, Luther JF, Sherrill JT, et al,. (2000). Social rhythm disruption and stressful life events in the onset of bipolar and unipolar episodes. Psychol Med 30: 1005-1016.
144. Malkoff-Schwartz S, Frank E, Anderson B, Sherrill JT, Siegel L, Patterson D, et al,. (1998). Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. Arch Gen Psychiatry 55: 702-707. (Pubitemid 28364386)
145. Manji HK, Bowden CL, Belmaker RH, (eds) (2000). Bipolar Medications: Mechanisms of Action. American Psychiatric Press: Washington DC.
146. Mansell W, Pedley R, (2008). The ascent into mania: a review of psychological processes associated with the development of manic symptoms. Clin Psychol Rev 28: 494-520. (Pubitemid 351308097)
147. Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, et al,. (2009). Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 206: 699-714.
148. Martinez-Aran A, Vieta E, Colom F, Torrent C, Sanchez-Moreno J, Reinares M, et al,. (2004). Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 6: 224-232. (Pubitemid 38702298)
149. Mavrikaki M, Nomikos GG, Panagis G, (2010). Efficacy of the atypical antipsychotic aripiprazole in d-amphetamine-based preclinical models of mania. Int J Neuropsychopharmacol 13: 541-548.
150. Mazza M, Bria P, Mazza S, (2007). Efficacy and safety of oxcarbazepine in bipolar disorder. Can J Psychiatry 52: 272. author reply 272-273. (Pubitemid 46743475)
151. McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, et al,. (2005). Regulation of dopaminergic transmission and cocaine reward by the clock gene. Proc Natl Acad Sci U S A 102: 9377-9381. (Pubitemid 40923571)
152. McElroy SL, Keck PE, Jr, (2000). Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 48: 539-557.
153. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J, (2009). Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11: 815-826.
154. McIntyre RS, Konarski JZ, Jones M, Paulsson B, (2007). Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms. J Affect Disord 100 (Suppl. 1): S5-14. (Pubitemid 46818457)
155. Meyendorff E, Lerer B, Moore NC, Bow J, Gershon S, (1985). Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment. Psychiatry Res 16: 303-308. (Pubitemid 16208558)
156. Miczek KA, O'Donnell JM, (1978). Intruder-evoked aggression in isolated and nonisolated mice: effects of psychomotor stimulants and L-dopa. Psychopharmacology (Berl) 57: 47-55. (Pubitemid 8338585)
157. Miczek KA, Maxson SC, Fish EW, Faccidomo S, (2001). Aggressive behavioral phenotypes in mice. Behav Brain Res 125: 167-181. (Pubitemid 33000455)
158. Minassian A, Young JW, (2010). Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother 11: 2107-2115.
159. Minassian A, Henry BL, Geyer MA, Paulus MP, Young JW, Perry W, (2009). The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 120: 200-206.
160. Mitchell PJ, (2005). Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526: 147-162. (Pubitemid 41744113)
161. Moller HJ, Rujescu D, (2010). Pharmacogenetics-genomics and personalized psychiatry. Eur Psychiatry 25: 291-293.
162. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H, (1997). Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58 (Suppl. 10): 37-44. (Pubitemid 27333179)
163. Morden B, Mitchell G, Dement W, (1967). Selective REM sleep deprivation and compensation phenomena in the rat. Brain Res 5: 339-349.
164. Mukherjee BP, Pradhan SN, (1976). Effects of lithium on foot shock-induced aggressive behavior in rats. Arch Int Pharmacodyn Ther 222: 125-131.
165. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al,. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128: 419-432.
166. O'Donnell KC, Gould TD, (2007). The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 31: 932-962. (Pubitemid 47299256)
167. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, et al,. (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24: 6791-6798. (Pubitemid 38993901)
168. Oehler J, Jahkel M, Schmidt J, (1985). [Effect of lithium, carbamazepine, ca-valproate and diazepam on changes in social isolation-induced behavior in mice]. Biomed Biochim Acta 44: 1523-1530. (Pubitemid 16194223)
169. Ong JC, Brody SA, Large CH, Geyer MA, (2005). An investigation of the efficacy of mood stabilizers in rodent models of prepulse inhibition. J Pharmacol Exp Ther 315: 1163-1171. (Pubitemid 41635404)
170. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G, (2000). Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2: 249-255.
171. Paulus M, Minassian A, Masten V, Feifel D, Geyer M, Perry W, (2007). Human Behavioral Pattern Monitor differentiates activity patterns of bipolar manic and attention deficit hyperactivity subjects. Biological Psychiatry 61: 227S.
172. Peet M, Peters S, (1995). Drug-induced mania. Drug Saf 12: 146-153.
173. Perry W, Minassian A, Feifel D, Braff DL, (2001). Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50: 418-424. (Pubitemid 32885591)
174. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, et al,. (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072-1080.
175. Perry W, Minassian A, Henry B, Kincaid M, Young JW, Geyer MA, (2010). Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Res 178: 84-91.
176. Pinel P, (1818). Nosographie Philosphique Ou La Methode De L'analyse Appliquee A Lamedecine, 6th edn. Brosson: Paris.
177. Poitou P, Boulu R, Bohuon C, (1975). Effect of lithium and other drugs on the amphetamine chlordiazeposice hyperactivity in mice. Experientia 31: 99-101.
178. Poolsup N, Li Wan Po A, de Oliveira IR, (2000). Systematic overview of lithium treatment in acute mania. J Clin Pharm Ther 25: 139-156. (Pubitemid 30326414)
179. Pope HG, Jr, McElroy SL, Keck PE, Jr, Hudson JI, (1991). Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 48: 62-68.
180. Popova E, Leighton C, Bernabarre A, Bernardo M, Vieta E, (2007). Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother 7: 617-626. (Pubitemid 46911611)
181. Post RM, Uhde TW, (1983). Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia 24 (Suppl. 2): S97-108. (Pubitemid 14150268)
182. Powell SB, Young JW, Ong JC, Caron MG, Geyer MA, (2008). Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav Pharmacol 19: 562-565.
183. Prasad V, Sheard MH, (1982). Effect of lithium upon desipramine enhanced shock-elicited fighting in rats. Pharmacol Biochem Behav 17: 377-378. (Pubitemid 12020813)
184. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, et al,. (2006). Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 26: 9022-9029. (Pubitemid 44319393)
185. Prien RF, Caffey EM, Jr, Klett CJ, (1972). Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 26: 146-153.
186. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA, (2001). Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J Neurosci 21: 305-313. (Pubitemid 32098754)
187. Ralph-Williams RJ, Paulus MP, Zhuang X, Hen R, Geyer MA, (2003). Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry 53: 352-359. (Pubitemid 36173965)
188. Redrobe JP, Nielsen AN, (2009). Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. Behav Brain Res 198: 481-485.
189. Reynolds B, (2006). A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol 17: 651-667.
190. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al,. (2007). Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A 104: 6406-6411. (Pubitemid 47186107)
191. Sachs GS, Gardner-Schuster EE, (2007). Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl s434: 27-34. (Pubitemid 47231066)
192. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al,. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356: 1711-1722. (Pubitemid 46658703)
193. Savitz J, Solms M, Ramesar R, (2005). Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord 7: 216-235. (Pubitemid 40778885)
194. Sax KW, Strakowski SM, Zimmerman ME, DelBello MP, Keck PE, Jr, Hawkins JM, (1999). Frontosubcortical neuroanatomy and the continuous performance test in mania. Am J Psychiatry 156: 139-141. (Pubitemid 29034894)
195. Schou M, Juel-Nielsen N, Stromgren E, Voldby H, (1954). The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry 17: 250-260.
196. Serretti A, Drago A, (2010). Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms. Neuropsychobiology 62: 61-71.
197. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH, (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J Neural Transm 109: 433-440. (Pubitemid 34251645)
198. Shaltiel G, Maeng S, Malkesman O, Pearson B, Schloesser RJ, Tragon T, et al,. (2008). Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 13: 858-872.
199. Shopsin B, Gershon S, Thompson H, Collins P, (1975). Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol. Arch Gen Psychiatry 32: 34-42.
200. Silverstone PH, Pukhovsky A, Rotzinger S, (1998). Lithium does not attenuate the effects of d-amphetamine in healthy volunteers. Psychiatry Res 79: 219-226. (Pubitemid 28346470)
201. Singh V, Muzina DJ, Calabrese JR, (2005). Anticonvulsants in bipolar disorder. Psychiatr Clin North Am 28: 301-323.
202. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D, (2007). Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 9: 551-560. (Pubitemid 47365622)
203. Spring G, Schweid D, Gray C, Steinberg J, Horwitz M, (1970). A double-blind comparison of lithium and chlorpromazine in the treatment of manic states. Am J Psychiatry 126: 1306-1310.
204. Sun T, Hu G, Li M, (2009). Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602: 334-342.
205. Suppes T, Calabrese JR, Mitchell PB, Pazzaglia PJ, Potter WZ, Zarin DA, (1995). Algorithms for the treatment of bipolar manic-depressive illness. Psychopharmacol Bull 31: 469-474. (Pubitemid 26036821)
206. Swerdlow NR, Braff DL, Taaid N, Geyer MA, (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139-154. (Pubitemid 24985903)
207. Swerdlow NR, Shoemaker JM, Stephany N, Wasserman L, Ro HJ, Geyer MA, (2002). Prestimulus effects on startle magnitude: sensory or motor? Behav Neurosci 116: 672-681. (Pubitemid 34793388)
208. Sylvia LG, Alloy LB, Hafner JA, Gauger MC, Verdon K, Abramson LY, (2009). Life events and social rhythms in bipolar spectrum disorders: a prospective study. Behav Ther 40: 131-141.
209. Szabo ST, Machado-Vieira R, Yuan P, Wang Y, Wei Y, Falke C, et al,. (2009). Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 56: 47-55.
210. Teng CT, Demetrio FN, (2006). Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr 28: 252-254. (Pubitemid 44506533)
211. Tohen M, Vieta E, (2009). Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 11 (Suppl. 2): 45-54.
212. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al,. (1999). Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156: 702-709. (Pubitemid 29220067)
213. Torres IJ, Defreitas CM, Defreitas VG, Bond DJ, Kunz M, Honer WG, et al,. (2010a). Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 41: 1-12.
214. Torres IJ, DeFreitas VG, DeFreitas CM, Kauer-Sant'Anna M, Bond DJ, Honer WG, et al,. (2010b). Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. J Clin Psychiatry 71: 1234-1242.
215. Vassout A, Veenstra S, Hauser K, Ofner S, Brugger F, Schilling W, Gentsch C, (2000). NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul Pept 96: 7-16.
216. Vasudev K, Macritchie K, Geddes J, Watson S, Young A, (2006). Topiramate for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 1: CD003384.
217. Wang J, Michelhaugh SK, Bannon MJ, (2007). Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur J Neurosci 25: 1982-1986. (Pubitemid 46581736)
218. Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G, (2008). Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. J Affect Disord 108: 1-9.
219. Yatham LN, Kusumaker V, (2003). Anticonvulsants in treatment of bipolar disorder. In:, Yatham LN, Kusumaker V, Kuthcer SP, (eds). Bipolar Disorder: A Clinician's Guide to Biological Treatments. Brunner-Routledge: New York, pp. 201-240.
220. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G, (2002). Third generation anticonvulsants in bipolar disorder: a review of efficacy and summary of clinical recommendations. J Clin Psychiatry 63: 275-283. (Pubitemid 34456353)
221. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF, (2008). Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65: 255-263. (Pubitemid 351342442)
222. Young AH, Geddes JR, Macritchie K, Rao SN, Watson S, Vasudev A, (2006). Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. Cochrane Database Syst Rev 3: CD004694.
223. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W, (2007). A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31: 882-896. (Pubitemid 47285352)
224. Young JW, Light GA, Marston HM, Sharp R, Geyer MA, (2009a). The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS ONE 4: e4227.
225. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA, (2009b). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122: 150-202.
226. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA, (2010a). GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) 208: 443-454.
227. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA, (2010b). The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacol Biochem Behav 96: 7-15.
228. Young JW, Goey AK, Minassian A, Perry W, Paulus MP, Geyer MA, (2010c). The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacology Biochem Behavior 96: 7-15.
229. Young JW, van Enkhuizen JE, Winstanley C, Geyer MA, (2011). Increased gambling behaviour in a mouse model of mania. J Psychopharmacol DOI: 10.1177/0269881111400646.
230. Zarate CA, Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA, et al,. (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9: 561-570. (Pubitemid 47365623)
231. Zdanys K, Tampi RR, (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 32: 1362-1374. (Pubitemid 352033662)
232. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, Caron MG, et al,. (2001). Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci U S A 98: 1982-1987. (Pubitemid 32165609)